Search

A good integration of dental implants and the surrounding soft tissue is essential to ensure the long-term effect of implant. In this review, we summarized the research progress of peri-implant soft tissue integration of dental titanium implants, with emphasis on the modification of the gingival interface of implants based on immune microenvironment regulation. This method influences the immune response around the implant by promoting the surface properties of implants, so as to enhance the peri-implant soft tissue integration. The purpose of this review is to provide reference for the related research and clinical application in the field of dental implantation.

Objective: To investigate the preventative effect of mutant kringle 5 (mK5) eye drops on corneal allograft rejection., Methods: It was a experimental study. The outbred strain F344 and Lewis rats were used as donors and recipients respectively. Sixty Lewis rats were randomly divided into B, C, D and E Group; Group A, F344 rats autograft control; Group B, allograft control (the control groups were given normal sodium only); Group C and D, allograft groups, were treated with 5 mg/L and 10 mg/L mK5 eye drops respectively; Group E, allograft group, was treated with 0.1% dexamethasone eye drops. The eye drops were applied one drop four times per day for two weeks, the occurrence and development of corneal allograft rejection and corneal neovascularization (CNV) was observed every other day by slit-lamp microscope, the grafts were evaluated clinically by means of Holland's scoring system and the area of CNV was calculated. Nine rats per group were killed on the 14th day, and the corneas were taken for histopathological examinations. Analysis of variance was used to analyze the outcomes., Results: The average graft survival time of Group B, C, D and E was (9.3 +/- 2.1), (21.1 +/- 7.3), (23.5 +/- 10.8) and (28.2 +/- 19.1) d respectively, Compared with Group B, Group C and D had a statistically significant prolongation of survival time (q = 10.24, 13.47; P < 0.05). Though treated with 0.1% dexamethasone eye drops (Group E) prolonged transplant survival time as compared with mK5 eye drops, but the difference was not statistically significant (q = 2.54, 1.49; P > 0.05). The occurrence of CNV in Group A was (3.1 +/- 0.8) d, Group B (2.6 +/- 0.5) d, Group C (6.4 +/- 0.5) d, Group D (7.8 +/- 0.7) d and Group E (5.3 +/- 1.0) d. Significant difference (q = 31.58, 51.21, 19.98; P < 0.05) was found between groups C, D, E and Group A. There were also significant difference between groups C, D, E and Group B (q = 43.87, 67.14, 24.53; P < 0.05). The CNV areas of Group C and Group D were also smaller than Group B (q = 30.76, 62.14; P < 0.05). The results was similar compared with Group E (q = 15.20, 25.64; P < 0.05). Fewer inflammatory cells and CNV were found in the cornea of the groups treated with mK5 eye drops., Conclusion: Topical application of mK5 eye drops can prevent corneal graft rejection and corneal neovascularization in rats.

Objective: To investigate the clinical efficacy and side effects of advanced non-small cell lung cancer (NSCLC) treated by combined gemcitabine and cisplatin., Methods: Forty-six patients with locally advanced (Stage IIIB) or metastatic (Stage IV) NSCLC were alloted to the study. The patients received gemcitabine 1 000 mg/m(2) on D 1, 8, and cisplatin 80 mg on D 1 approximately 3 in the 21-day cycle., Results: An objective response was obtained in 46% (21/46) of patients (1 CR and 21 PR), whereas 19 patients had stable disease and 6 patients showed progressive disease. The response rate was 58.3% in untreated patients and 31.8% was obtained in treated ones. Significant difference was observed between the two groups (P < 0.05). The main toxicities were leukopenia and thrombocytopenia., Conclusion: The combination of gemcitabine and cisplatin, being feasible and well-tolerated, should be taken as an energetic scheme in the treatment of advanced NSCLC.

One hundred and fifteen patients with inoperable esophageal carcinoma were treated by either chemotherapy alone or chemotherapy plus Rabdosia rubescens. In group A, out of 31 patients treated with pingyangmycin (P) and nitrocaphane (N), 10 (32.3%) responded to the treatment. Among them, 2 showed partial response (greater than 50% tumor regression) and 8 minimal response (greater than 50% tumor regression). In group B, out of 84 patients treated with PN plus Rabdosia rubescens, 59 (70.2%) responded. Of them, 10 showed complete response (100% tumor regression), 16 partial response and 33 minimal response. the one-year survival rates of group A and B were 13.6% and 41.3%. Statistical significance was present in these two groups both in the response rate and one-year survival rate. As regards the drug toxicity, there was no significant difference between these two groups. Alopecia, anorexia, nausea and hyperpyrexia occurred in more than 30% of patients. Mild leukopenia and thrombocytopenia and interstitial pneumonia were noted in some patients, and two patients died of toxicity in the lungs.